Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human…
Luglio 2019
-
-
Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy…
-
ECG Assessments During The Development Of Oncology Compounds Thijs van Iersel, MD Borje Darpo, MD,…
-
Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative…
-
Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer J…
-
Cardiac risk in the treatment of breast cancer: assessment and management Antonis Valachis and Cecilia Nilsson Breast…
-
Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients’ heart? Fontanella C, Aita M, Cinausero…
-
Cancer therapy and cardiovascular risk: focus on bevacizumab Panagiota Economopoulou, Athanasios Kotsakis, Ioannis Kapiris, and Nikolaos Kentepozidis…
-
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors…
-
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level…